Clinical pharmacological study of mitiglinide in type 2 diabetes patients with voglibose monotherapy

Japanese Pharmacology and Therapeutics

Volumn 35, Issue SUPPL. 1, 2007, Pages

  Toh, Yasuo ^a   Origasa, Hideki ^b   Akanuma, Yasuo ^c  

^a Medical Association Kunwa Kai Aiwa Clinic

^b UNIVERSITY OF TOYAMA   (Japan)

^c INSTITUTE FOR ADULT DISEASES   (Japan)

Author keywords

Mitiglinide; Postprandial blood glucose; Voglibose

Indexed keywords

GLUCOSE; MITIGLINIDE; VOGLIBOSE;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DIET THERAPY; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; HUMAN; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; SINGLE DRUG DOSE;

EID: 34250796232     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. The Diabetes Control and Complication Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 ; 329 : 977-86.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 ; 352 : 837-53.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 ; 352 : 854-65.
4. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Plact 1995 ; 28 : 103-17.
5. Mogami H, Shibata H, Nobusawa R, Ohnota H, Satou F, Miyazaki J, et al. Inhibition of ATP-sensitive K channel by a non-sulfonylurea compound KAD-1229 in a pancreatic b-cell line, MIN 6 cell. Eur J Pharmacol 1994 ; 269 : 293-8.
6. Ohnota H, Koizumi T, Tsutsumi N, Kobayashi M, Inoue S, Sato F. Novel Rapid- and short-acting hypoglycemic agent, a calcium (2S)-2-benzyl-3- (cis-hexahydro-2-isoindolininylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor : comparison of effects between (KAD-1229) and gliclazide. J Pharmacol Exp Ther 1994 ; 269 : 489-95.
7. Japanese source